Background: Eradication of hepatitis C virus (HCV) infection using direct-acting antiviral Agents (DAAs) nowadays is almost always hopeful. Sustained virological response (SVR) has been documented in more than 90% of cases. This prevents more fibrosis and precludes the progression of portal hypertension (PH). Objective: detect the effect of HCV Direct Antiviral Agents on portal circulation hemodynamics. Patients and methods: This prospective descriptive study that was conducted on 70 HCV infected patients with liver stiffness measurement (LVM) ≥ 14.0 Kpa and underwent treatment with DAAs therapeutic regimens. They were subjected to pre-treatment, end of treatment (EOT) and 1 year after EOT laboratory, transient elastography (TE) and Doppler assessment at Gastroenterology, Hepatology and Infectious diseases Department, Al-Hussien University Hospital, Cairo and National Liver Institute, Menoufia, Egypt in the period from May 2018 to December 2019. Results: Liver function tests including serum bilirubin, albumin, international ratio (INR), alanine transaminase (ALT) and aspartate transaminase (AST) were improved with variable significant values at EOT and 1 year after treatment, while hemoglobin and platelet count decreased. LVM values decreased significantly at the end of treatment (P<0.001). Doppler parameters including portal vein diameter, portal vein velocity (PVV), congestion index of portal vein (CI) and liver vascular index (P value<0.001) were improved significantly 1year after EOT. Also, resistive index of hepatic artery (HARI) (P value = 0.001) significantly improved at the same point of time. Conclusion: Doppler portal hypertensive parameters, as a marker of portal hypertension, improved in parallel with the improvement in LVM, ALT and AST values after viral eradication.